HRTX vs. XBI
Compare and contrast key facts about Heron Therapeutics, Inc. (HRTX) and SPDR S&P Biotech ETF (XBI).
XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: HRTX or XBI.
Key characteristics
| HRTX | XBI | |
|---|---|---|
| YTD Return | -30.00% | 2.99% |
| 1Y Return | 29.80% | 31.15% |
| 3Y Return (Ann) | -52.79% | -9.63% |
| 5Y Return (Ann) | -44.04% | 1.69% |
| 10Y Return (Ann) | -17.41% | 5.08% |
| Sharpe Ratio | 0.41 | 1.10 |
| Sortino Ratio | 1.23 | 1.64 |
| Omega Ratio | 1.17 | 1.19 |
| Calmar Ratio | 0.38 | 0.49 |
| Martin Ratio | 1.30 | 3.79 |
| Ulcer Index | 29.58% | 7.75% |
| Daily Std Dev | 93.91% | 26.68% |
| Max Drawdown | -99.96% | -63.89% |
| Current Drawdown | -99.91% | -47.12% |
Correlation
The correlation between HRTX and XBI is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
HRTX vs. XBI - Performance Comparison
In the year-to-date period, HRTX achieves a -30.00% return, which is significantly lower than XBI's 2.99% return. Over the past 10 years, HRTX has underperformed XBI with an annualized return of -17.41%, while XBI has yielded a comparatively higher 5.08% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
HRTX vs. XBI - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Heron Therapeutics, Inc. (HRTX) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
HRTX vs. XBI - Dividend Comparison
HRTX has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.16%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
HRTX Heron Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.16% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% | 1.07% | 0.17% |
Drawdowns
HRTX vs. XBI - Drawdown Comparison
The maximum HRTX drawdown since its inception was -99.96%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for HRTX and XBI. For additional features, visit the drawdowns tool.
Volatility
HRTX vs. XBI - Volatility Comparison
Heron Therapeutics, Inc. (HRTX) has a higher volatility of 38.95% compared to SPDR S&P Biotech ETF (XBI) at 8.44%. This indicates that HRTX's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.